ClinicalTrials.gg
Active, not recruitingNCT06305559REMBRANDTUpdated Apr 9, 2026

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

A Phase 3 interventional study of obicetrapib 10 mg + ezetimibe 10 mg FDC daily and Placebo in Lipidemia, Coronary Artery Disease and Plaque, Atherosclerotic, sponsored by NewAmsterdam Pharma. Active, not recruiting at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by NewAmsterdam Pharma · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 338 studies in Hyperlipidemias with a site in United States — 30 open to participants now, 45 under way, 10 of them phase 3. Hyperlipidemias · United States.

Planned enrollment
95th of 306
300 · median 120
Started
2024
with 16 others
Phase 3
73 of 338
3 open now
Primary completion
2027-11
later than 27 of 44 live
Registered
304th of 338
by date

Among the 338 studies in Hyperlipidemias with a site in United States, this one is the 95th largest by planned enrollment of the 306 interventional ones that give a count, is one of 17 that started in 2024, is one of 73 in phase 3, reaches primary completion later than 27 of the 44 other live ones, and was the 304th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 338 studies in Hyperlipidemias with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 338 studies in Hyperlipidemias with a site in United States, or all of them as a file.
02

Study summary

This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).

03

Conditions studied

  • Lipidemia
  • Coronary Artery Disease
  • Plaque, Atherosclerotic
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting serum LDL-C ≥70 mg/dL (≥1.81 mmol/L)
  • Evaluable non-calcified plaque of at least 75 mm3 in the major epicardial coronary arteries
  • 18-40, inclusive
  • Max tolerated lipid modifying therapy
  • Estimated ≥40 mL/min/1.73 m2

Exclusion criteria

Exclusion Criteria:

  • ≥10.0% (≥0.100 fraction) or a fasting glucose ≥270 mg/dL (≥15.0 mmol/L) at Screening
  • for CCTA
  • History of coronary artery bypass graft
  • Active liver disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Obicetrapib/Ezetimibe

    obicetrapib 10 mg + ezetimibe 10 mg FDC daily

    Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily

  • Placebo comparator
    Placebo

    Placebo on top of baseline lipid modifying therapy

    Other: Placebo

Interventions

  • Drugobicetrapib 10 mg + ezetimibe 10 mg FDC daily

    Drug page: TA-8995

    Active treatment

    Also known as: FDC

  • OtherPlacebo

    Baseline lipid modifying therapy

06

What researchers measure

Primary outcomes

  1. • To evaluate the effect of obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) daily on total non-calcified coronary atherosclerotic plaque volume (NCPV) at 18 months.

    Total plaque comparison measured by CCTA

    Time frame: 18 months

Secondary outcomes

  1. Absolute change from baseline to 18 months in total NCPV in all major epicardial coronary arteries, as measured by CCTA, in participants treated with obicetrapib 10 mg + ezetimibe 10 mg FDC therapy compared with placebo.

    Total change in NCPV as measured by CCTA

    Time frame: 18 Months

  2. Percent change from baseline to 18 months in LDL-C in participants treated with obicetrapib 10 mg + ezetimibe 10 mg FDC therapy compared to placebo.

    Change in LDL-C levels measured by central lab

    Time frame: 18 Months

  3. Percent change from baseline to 18 months in non-calcified coronary atherosclerotic plaque volume in the most diseased coronary segment (NCPVMD), as measured by CCTA, in participants treated with FDC therapy vs placebo

    Percent change in plaque volume in most diseased coronary arteries measured by CCTA

    Time frame: 18 Months

  4. Absolute change from baseline to 18 months in NCPVMD, as measured by CCTA, in participants treated with obicetrapib 10 mg + ezetimibe 10 mg FDC therapy compared with placebo.

    Absolute change in plaque volume in most diseased coronary arteries measured by CCTA

    Time frame: 18 Months

  5. Change in perivascular fat attenuation index (FAI), FAI score and its age- and gender specific centile in the principal epicardial coronary arteries as measured by CCTA in participants treated with FDC therapy compared with placebo.

    Changes in coronary arterial fat composition measured by CCTA

    Time frame: 18 Months

07

Study locations

1 site
  • NGMR
    Hialeah, Florida 33016, United States
08

References and documents

Publications

  • McCarthy CP, Ballantyne CM, Blankstein R, Budoff MJ, Ditmarsch M, Gibson CM, Kastelein JJP, Navar AM, Nicholls SJ, Ray KK, Shirodaria C, Williams MC, Januzzi JL Jr. Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec;290:325-338. doi: 10.1016/j.ahj.2025.07.012. Epub 2025 Jul 17. PubMed 40683616 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Nov 2027, 42 months after the start.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 42 months is above that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Mar 12, 2024
StartActual
May 16, 2024
Primary completionEst.
Nov 2027
CompletionEst.
Feb 2028
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06305559
Lead sponsor
NewAmsterdam Pharma
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
May 16, 2024
Primary completion
Nov 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Apr 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion